Penn study: Inconsistent GLP‑1 use may lead to weight gain
6abc Philadelphia • • health
Key Points:
- A University of Pennsylvania study found that intermittent use of GLP-1 weight loss drugs, such as semaglutide (Ozempic), may reduce their effectiveness and lead to fat gain in mice.
- Researchers observed that mice cycled on and off the drug gained weight and fat, suggesting the development of therapeutic resistance after interruptions.
- GLP-1 medications have become popular, with about one in eight adults using them, but over half of users discontinue within two years, often restarting later, which may diminish the drug's benefits.
- Although the study was conducted on mice, the findings raise concerns about intermittent use in humans, highlighting the importance of consistent medication adherence for sustained weight loss.
- Further research is needed to explore if similar effects occur with other weight-loss drugs, including newer treatments like those in Zepbound.